Parkin antibody (ab43550)

Product Name 

Parkin antibody

Product type 

Primary antibodies

Description 

Mouse polyclonal to Parkin

Immunogen 

Vector coding for a partial recombinant fusion protein, corresponding to amino acids 328-428 of Fruit fly (Drosophila melanogaster) Parkin.
Target sequence used to make the antibody: LTREEYDRYQ RFATEEYVLQ AGGVLCPQPG CGMGLLVEPD CRKVTCQNGC GYVFCRNCLQ GYHIGECLPE GTGASATNSC EYTVDPNRAA EARWDEASNV.
BLAST 'LTREEYDRYQ RFATEEYVLQ AGGVLCPQPG CGMGLLVEPD CRKVTCQNGC GYVFCRNCLQ GYHIGECLPE GTGASATNSC EYTVDPNRAA EARWDEASNV ' with or

Reacts with 
(species key)

Dm

Tested applications 
(see key)

WB

Abreviews 

Customer reviews (see key)

Read about Abreviews

Application notes 
(see key)

Recommended dilutions
WB: 1/1000. Predicted molecular weight: 54 kDa.

This antibody has been tested in Western blot against an E.coli lysate containing the partial recombinant fusion protein used as an immunogen. We have no data on detection of endogenous protein.

Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.

Cellular localization 

Cytoplasmic

Research areas 

Cell Biology >> Proteolysis / Ubiquitin >> Proteasome / Ubiquitin >> Ubiquitin E2s and E3s >> RING Finger E3 Ligase
Neuroscience >> Neurology process >> Neurodegenerative disease >> Parkinson's disease >> Parkin / PARK

Relevance 

Parkinson's Disease, the second most common neurodegenerative disease after Alzheimer's Disease, is characterized by the loss of dopaminergic neurons and the presence of Lewy bodies (comprised of alpha synuclein and parkin inclusions). Autosomal Recessive Juvenile Parkinsonism (AR-JP) is a recently described form of Parkinson's Disease that has been linked to a gene that codes for parkin. Parkin, a 52 kDa protein, has a suggested role in the ubiquitin/proteasome pathway for protein degradation. The amino terminus bears sequence homology to ubiquitin while functionally it acts as a RING type ubiquitin protein ligase (E3) that coordinates the transfer of ubiquitin to substrate proteins, thus targeting them for degradation by the proteasome.

This antibody was raised by a genetic immunization technique. Genetic immunization can be used to generate antibodies by directly delivering antigen-coding DNA into the animal, rather than injecting a protein or peptide (Tang et al. PubMed: 1545867; Chambers and Johnston PubMed 12910245; Barry and Johnston PubMed: 9234514). The animal's cells produce the protein, which stimulates the animal's immune system to produce antibodies against that particular protein.

A vector coding for a partial fusion protein was used for genetic immunisation of a mouse and the resulting serum was tested in Western blot against an E.coli lysate containing that partial fusion protein.

Genetic immunization offers enormous advantages over the traditional protein-based immunization method. DNA is faster, cheaper and easier to produce and can be produced by standard techniques readily amenable to automation. Furthermore, the antibodies generated by genetic immunization are usually of superior quality with regard to specificity, affinity and recognizing the native protein.’

Database links 

Raised in 

Mouse

Clonality 

Polyclonal

Isotype 

IgG

Purity 

Whole antiserum

Storage buffer 

Preservative: None
Constituents: 50% Glycerol, Whole serum

Material safety datasheet (MSDS) for this product:
Glycerol MSDS

Form 

Liquid

Concentration 

Concentration not determined - why is this?

Storage instructions 

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Customer reviews (feedback) regarding Parkin antibody

Customer FAQs regarding Parkin antibody

Protocols for Parkin antibody

Price and availability of products related to Parkin antibody

Parkin antibody - related products: